Other Operating Expenses

Other operating expenses were comprised as follows:

Other Operating Expenses

 

 

2015

 

2016

 

 

€ million

 

€ million

2015 figures restated

Losses on retirements of noncurrent assets

 

(32)

 

(22)

Impairment losses on receivables

 

(183)

 

(171)

Expenses related to significant legal risks

 

(151)

 

(262)

Losses from derivatives

 

(626)

 

(181)

Miscellaneous operating expenses

 

(283)

 

(298)

Total

 

(1,275)

 

(934)

of which special items

 

(247)

 

(205)

Of the impairment losses on receivables, €115 million pertained to past-due receivables in Brazil. In 2015, impairment losses of €91 million were recognized on receivables from the Venezuelan exchange control authority because the authority did not allocate U.S. dollars at the subsidized exchange rate with respect to the full amounts of older receivables.

The €262 million in expenses for significant legal risks mainly included accounting measures taken in connection with legal proceedings relating to the products Xarelto™, Essure™ and Cipro™/Avelox™. In 2015, the €151 million in expenses for significant legal risks mainly included accounting measures taken in connection with legal proceedings relating to the products Luna™, LL Rice™ and Xarelto™.

Miscellaneous operating expenses included €48 million (2015: €51 million) in donations to charitable causes (all segments). Expenses of €34 million pertained to provisions established for environmental protection measures in the United States (Crop Science segment).

As in the previous year, the remaining amount of miscellaneous operating expenses comprised a large number of individually immaterial items at the subsidiaries.